Terms ending in 2042
Every in-force patent on Ono Pharmaceutical Co., Ltd.'s record whose computed term ends in 2042, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,981,682 | SUBSTITUTED CYCLOPENTA[c]PYRROLES AS ABHD6 ANTAGONISTS In force · High confidence | Ono Pharmaceutical Co., Ltd. | In force | High confidence | |
| US 12,600,730 | SUBSTITUTED CYCLOPENTA[c]PYRROLES AS ABHD6 ANTAGONISTS In force · High confidence | Ono Pharmaceutical Co., Ltd. | In force | High confidence | |
| US 12,234,289 | Immunosuppresive Agent In force · High confidence | Ono Pharmaceutical Co., Ltd. | In force | High confidence | |
| US 12,240,903 | Biomarkers for determining the effectiveness of immune checkpoint inhibitors In force · High confidence | Ono Pharmaceutical Co., Ltd. | In force | High confidence | |
| US 12,447,150 | Treatment of Cancer by Combination of Immune Checkpoint Inhibitor and Folfirinox Therapy In force · High confidence | Ono Pharmaceutical Co., Ltd. | In force | High confidence | |
| US 12,459,890 | Salt and Crystal Form of Compound Having Agonistic Activity to S1P5 Receptor In force · High confidence | Ono Pharmaceutical Co., Ltd. | In force | High confidence | |
| US 12,571,799 | Biomarkers for Determining the Efficacy of Immune Checkpoint Inhibitors In force · High confidence | Ono Pharmaceutical Co., Ltd. | In force | High confidence | |
| US 12,325,746 | Bispecific Antibody In force · High confidence | Ono Pharmaceutical Co., Ltd. | In force | High confidence |
8 of 8 patents shown. Soonest term end first, then patent number.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.